Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions
出版年份 2014 全文链接
标题
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 5, Pages 611-628
出版商
Informa Healthcare
发表日期
2014-03-26
DOI
10.1517/13543784.2014.902442
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an HSP90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
- (2017) C. P. Schroder et al. JOURNAL OF CLINICAL ONCOLOGY
- An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
- (2017) G. D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Posttranslational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors
- (2015) Kristin Beebe et al. Oncotarget
- A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
- (2013) Jonathan W Goldman et al. BMC CANCER
- A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
- (2013) Shanu Modi et al. BREAST CANCER RESEARCH AND TREATMENT
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer
- (2013) D. A. Proia et al. CLINICAL CANCER RESEARCH
- Reply to M.C. Garassino et al
- (2013) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Experimental and Structural Testing Module to Analyze Paralogue-Specificity and Affinity in the Hsp90 Inhibitors Series
- (2013) Tony Taldone et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
- (2012) M. A. Dickson et al. ANNALS OF ONCOLOGY
- Recent updates on the development of ganetespib as a Hsp90 inhibitor
- (2012) Hyun Kyung Choi et al. ARCHIVES OF PHARMACAL RESEARCH
- Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90
- (2012) Joerg Bussenius et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
- (2012) K. H. T. Paraiso et al. CLINICAL CANCER RESEARCH
- A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors
- (2012) K. Jhaveri et al. CLINICAL CANCER RESEARCH
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
- (2012) L. Neckers et al. CLINICAL CANCER RESEARCH
- Very Superstitious
- (2012) Mikkael A. Sekeres JOURNAL OF CLINICAL ONCOLOGY
- Discovery of (2S)-1-[4-(2-{6-Amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a Purine-Based Hsp90 Inhibitor
- (2012) Se-Ho Kim et al. JOURNAL OF MEDICINAL CHEMISTRY
- Abstract A96: Phase 1 study of HSP90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer.
- (2012) W. E. Samlowski et al. MOLECULAR CANCER THERAPEUTICS
- The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo
- (2012) D. L. Menezes et al. MOLECULAR CANCER THERAPEUTICS
- HSP90 as a platform for the assembly of more effective cancer chemotherapy
- (2011) Luke Whitesell et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
- (2011) Komal Jhaveri et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
- (2011) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
- (2011) A. Rajan et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
- (2011) Simon Pacey et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment
- (2011) Hardik J Patel et al. Expert Opinion on Drug Discovery
- A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma
- (2011) David Siegel et al. LEUKEMIA & LYMPHOMA
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- Many faces of a cancer-supporting protein
- (2011) John F. Darby et al. NATURE
- Biogen Idec restructures, sharpens neurology focus
- (2011) Peter Mitchell NATURE BIOTECHNOLOGY
- Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
- (2011) Kamalika Moulick et al. Nature Chemical Biology
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
- (2011) William K. Oh et al. UROLOGY
- Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90
- (2010) Patrick Fadden et al. CHEMISTRY & BIOLOGY
- A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
- (2010) Simon Pacey et al. INVESTIGATIONAL NEW DRUGS
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome
- (2010) Yoon-Jae Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
- (2010) Andrew J. Woodhead et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency
- (2010) Christopher W. Murray et al. JOURNAL OF MEDICINAL CHEMISTRY
- 89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
- (2010) W. B. Nagengast et al. JOURNAL OF NUCLEAR MEDICINE
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
- (2010) J E Lancet et al. LEUKEMIA
- Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab
- (2010) Jason P. Holland et al. PLoS One
- Hsp90 and co-chaperones twist the functions of diverse client proteins
- (2009) Abbey Zuehlke et al. BIOPOLYMERS
- CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
- (2009) R. Bao et al. CLINICAL CANCER RESEARCH
- Purine-Scaffold Hsp90 Inhibitors
- (2009) Tony Taldone et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
- (2009) Shivaani Kummar et al. EUROPEAN JOURNAL OF CANCER
- 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft
- (2009) Thijs H. Oude Munnink et al. EUROPEAN JOURNAL OF CANCER
- Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
- (2008) D. B. Solit et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies
- (2008) S. S. Ramalingam et al. CLINICAL CANCER RESEARCH
- Just Enough Palliation: Radiation Dose and Outcome in Patients With Non–Small-Cell Lung Cancer
- (2008) Henry Wagner JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now